This article has multiple issues. Please help or discuss these issues on the talk page. (Learn how and when to remove these template messages)
This article needs additional citations for verification. Please help by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: – ···scholar·JSTOR(June 2018) (Learn how and when to remove this template message)
This article's lead sectionmay be too short to adequately summarize the key points. Please consider expanding the lead to provide an accessible overview of all important aspects of the article.(June 2018)
This article is an orphan, as no other articles . Please introduce links to this page from ; try the Find link tool for suggestions. (January 2019)
(Learn how and when to remove this template message)
Very early onset inflammatory bowel disease (VEOIBD) is a type of IBD which starts in people younger than 6 years of age. According to age we can distinguish more specifically two categories within the VEOIBD diagnosis - neonatal IBD (patients younger than 1 month) and infantile IBD (patients younger than 2 years old).[1]
VEIOBD patients present with severe form of the disease that responds poorly to conventional therapies. The symptoms often include not only gastrointestinal tract, but also other tissues, such as pituitary gland, spleen, liver, skin, respiratory tract or blood.[1]
Inflammatory bowel diseases (IBDs), such as Crohn Disease (CD) or Ulcerative Colitis (UC), are chronic inflammatory conditions of the gastrointestinal tract. Up-to-date findings show that the pathogenesis is influenced by both environmental and genetic factors. A considerable number of monogenic disorders can be found especially among patients with VEOIBD. Causal mutations can be found in genes involved in epithelial barrier formation (COL7A1, FERMT1), innate (CYBB, G6PC3), as well as the specific immune response and immune regulation (IL10, IL10RA, FOXP3).[3]